Evidence map›Paper›PMID 40738879›Full record

ArticleSignal transduction and targeted therapy2025

Dynamics of neutralizing antibodies against COVID-19 Omicron subvariants following breakthrough infection in southwest China between December 2022 and April 2024.

Yongquan He, Yi Yin, Yi Zhang, Huiping Yang, Zhiling Jiang, Fang Hao, Taiqiang Zhao, Xiaobin Liu, Yusong Liu, Yong Zeng and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Signal transduction and targeted therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Yongquan He *Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Department of Laboratory Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Yi Yin *Prenatal Diagnosis Center, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Yi Zhang *Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Department of Laboratory Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Huiping Yang *Institute of Microbiological Detection and Analyses, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan, China.
Zhiling JiangSichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Department of Laboratory Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Fang HaoSichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Department of Laboratory Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Taiqiang ZhaoSichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Department of Laboratory Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Xiaobin LiuHealth Care Department, School of Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Yusong LiuSichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Department of Laboratory Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Yong ZengDepartment of Ophthalmology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Xi LiSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Xuemei ChenInfectious Disease Department, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Kaiju XuInfectious Disease Department, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Chang TanSichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Department of Laboratory Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Jie YangSichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Department of Laboratory Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Li JiangSichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Department of Laboratory Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Bo GongSichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Department of Laboratory Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Zhenglin YangSichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Department of Laboratory Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China. yangzhenglin@cashq.ac.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

From December 2022 to January 2023, the SARS-CoV-2 Omicron BA.5/BF.7 variant significantly impacted mainland China. While most COVID-19 patients experienced mild symptoms and were treated as outpatients or at home, some cases progressed to severe illness, necessitating hospitalization or even resulting in death. To better understand this outbreak and forecast future waves as SARS-CoV-2 continues to evolve, it is crucial to assess the titer of neutralizing antibodies (Nab) for evaluating the establishment of an immune barrier. In this study, we investigated the dynamic evolution of humoral immunity following the breakthrough infection wave driven by the SARS-CoV-2 Omicron BA.5/BF.7 variant in southwest China. Over a period of more than one year, we analyzed 3128 serum samples collected monthly to delineate the kinetics of Nab responses in a large cohort. Our data revealed a pronounced surge in Nab titers immediately after the December 2022-January 2023 outbreak, particularly among individuals primed with two or three doses of vaccine. As the epidemic progressed, emerging variants such as XBB.1.5, EG.5, and JN.1 elicited distinct immunological responses and demonstrated varying capacities for immune escape. Our findings underscore the rapid antigenic evolution of SARS-CoV-2 and the consequent challenges in sustaining effective population-level immunity, thereby advocating for continual surveillance and adaptive vaccine immunogen updates.

Indexed as

Antibodies, NeutralizingAntibodies, ViralCOVID-19SARS-CoV-2AdultBreakthrough InfectionsChinaCOVID-19 VaccinesFemaleHumansMaleMiddle AgedAntibodies, NeutralizingAntibodies, ViralCOVID-19 Vaccines

Identifiers

PMID40738879
PMCPMC12310930

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.